Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559
clinical_inquiry_hub@lilly.com


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting

Open to: ALL

Age: 1.0 - 39.0

Medical Conditions


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jan 2020 May 2027

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Administered IV

Intervention Arm Group : Ramucirumab + Cyclophosphamide + Vinorelbine (DSRCT ISA);Ramucirumab + Gemcitabine + Docetaxel (SS ISA);

Intervention Type : DRUG
Intervention Description : Administered orally

Intervention Arm Group : Cyclophosphamide + Vinorelbine (DSRCT ISA);Ramucirumab + Cyclophosphamide + Vinorelbine (DSRCT ISA);

Intervention Type : DRUG
Intervention Description : Administered IV

Intervention Arm Group : Cyclophosphamide + Vinorelbine (DSRCT ISA);Ramucirumab + Cyclophosphamide + Vinorelbine (DSRCT ISA);

Intervention Type : DRUG
Intervention Description : Administered IV

Intervention Arm Group : Gemcitabine + Docetaxel (SS ISA);Ramucirumab + Gemcitabine + Docetaxel (SS ISA);

Intervention Type : DRUG
Intervention Description : Administered IV

Intervention Arm Group : Gemcitabine + Docetaxel (SS ISA);Ramucirumab + Gemcitabine + Docetaxel (SS ISA);

Intervention Type : DRUG
Intervention Description : Administered orally

Intervention Arm Group : Abemaciclib + Irinotecan + Temozolomide (ES ISA);

Intervention Type : DRUG
Intervention Description : Administered IV

Intervention Arm Group : Abemaciclib + Irinotecan + Temozolomide (ES ISA);Irinotecan + Temozolomide (ES ISA);

Intervention Type : DRUG
Intervention Description : Administered orally

Intervention Arm Group : Abemaciclib + Irinotecan + Temozolomide (ES ISA);Irinotecan + Temozolomide (ES ISA);



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Royal Marsden Hospital
    London
    SW3 6JJ
  • Royal Manchester Children's Hospital
    Manchester
    M139WL
  • University College Hospital - London
    London
    Greater London
    NW1 2BU
  • The Christie NHS Foundation Trust
    Manchester
    M20 4BX

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559
clinical_inquiry_hub@lilly.com



The study is sponsored by Eli Lilly and Company




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT05999994
Last updated 18 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.